Invesco
ADCT icon

Invesco’s ADC Therapeutics ADCT Stock Holding History

Invesco’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156K Buy
41,630
+1,419
+4% +$5.59K ﹤0.01% 3552
2025
Q4 		$142K Buy
40,211
+1,422
+4% +$5.77K ﹤0.01% 3598
2025
Q3 		$155K Sell
38,789
-93,429
-71% -$295K ﹤0.01% 3615
2025
Q2 		$354K Sell
132,218
-486
-0.4% -$1.02K ﹤0.01% 3307
2025
Q1 		$187K Buy
132,704
+98,335
+286% +$167K ﹤0.01% 3525
2024
Q4 		$68.4K Buy
34,369
+1,700
+5% +$4.45K ﹤0.01% 3667
2024
Q3 		$103K Sell
32,669
-290
-0.9% -$915 ﹤0.01% 3617
2024
Q2 		$104K Buy
+32,959
New +$131K ﹤0.01% 3745
2022
Q1 		– Sell
-242,643
Closed -$4.9M – 4000
2021
Q4 		$4.9M Buy
242,643
+19,045
+9% +$459K ﹤0.01% 2420
2021
Q3 		$6.07M Sell
223,598
-2,110
-0.9% -$54K ﹤0.01% 2282
2021
Q2 		$5.5M Sell
225,708
-8,146
-3% -$189K ﹤0.01% 2387
2021
Q1 		$5.71M Buy
233,854
+3,692
+2% +$107K ﹤0.01% 2313
2020
Q4 		$7.37M Buy
230,162
+70,386
+44% +$2.31M ﹤0.01% 1966
2020
Q3 		$5.27M Buy
+159,776
New +$6.92M ﹤0.01% 1983

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco's ADCT Position: Q1 2026 in Review

Invesco increased its ADC Therapeutics (ADCT) stake by 3.5% in Q1 2026, buying an estimated $5.59K and bringing the position to 41,630 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #3552.

Invesco first reported a position in ADCT in Q3 2020 and has held it in 14 quarters since. The position peaked at $7.37M in Q4 2020. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Invesco held 41,630 shares of ADC Therapeutics worth $156K as of Q1 2026.
  • Invesco bought 1,419 ADC Therapeutics shares in Q1 2026, an estimated $5.59K.
  • ADC Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3552 holding.
  • Invesco first reported a position in ADC Therapeutics in Q3 2020 and has held it in 14 quarters since.
  • Invesco's ADC Therapeutics position peaked at $7.37M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.